RT Journal
A1 Kuehn BM
T1 SCientists find promising therapies for fragile x and down syndromes
JF JAMA
JO JAMA
YR 2011
FD January 26
VO 305
IS 4
SP 344
OP 346
DO 10.1001/jama.2010.1960
UL http://dx.doi.org/10.1001/jama.2010.1960
AB 
Advances in the understanding of the genetic and molecular basis of developmental disorders, as well as the creation of mouse models for these conditions, have led scientists studying them to some surprising insights. Even later in life, mice with Down syndrome or fragile X syndrome (FXS) that are given targeted treatment can experience improvements in cognitive function. Findings from such animal studies have paved the way to human trials to assess some of these potential therapies, with some experimental therapies for FXS already entering late-stage clinical trials.